185 related articles for article (PubMed ID: 14716180)
1. Low-dose transdermal estradiol for symptomatic perimenopause.
Shulman LP; Harari D
Menopause; 2004; 11(1):34-9. PubMed ID: 14716180
[TBL] [Abstract][Full Text] [Related]
2. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
[TBL] [Abstract][Full Text] [Related]
3. Treatment of vasomotor symptoms during perimenopause.
Desindes S
Menopause; 2004; 11(1):2-4. PubMed ID: 14716175
[No Abstract] [Full Text] [Related]
4. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms.
Mizunuma H
Climacteric; 2011 Oct; 14(5):581-9. PubMed ID: 21848497
[TBL] [Abstract][Full Text] [Related]
5. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
[TBL] [Abstract][Full Text] [Related]
6. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
7. Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms.
Kaszkin-Bettag M; Ventskovskiy BM; Solskyy S; Beck S; Hasper I; Kravchenko A; Rettenberger R; Richardson A; Heger PW
Altern Ther Health Med; 2009; 15(1):24-34. PubMed ID: 19161045
[TBL] [Abstract][Full Text] [Related]
8. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
Samsioe G; Dvorak V; Genazzani AR; Hamann B; Heikkinen J; Mueck AO; Suzin J; Kawakami FT; Ferreira A; Sun D; Arguinzoniz M
Maturitas; 2007 Jun; 57(2):171-81. PubMed ID: 17317046
[TBL] [Abstract][Full Text] [Related]
9. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms.
Utian WH; Speroff L; Ellman H; Dart C
Menopause; 2005; 12(6):708-15. PubMed ID: 16278614
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women.
Archer DF;
Menopause; 2003; 10(6):516-21. PubMed ID: 14627859
[TBL] [Abstract][Full Text] [Related]
11. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.
Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB; Lambrecht LJ
Menopause; 2009; 16(1):132-40. PubMed ID: 18971794
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life.
Soares CN; Arsenio H; Joffe H; Bankier B; Cassano P; Petrillo LF; Cohen LS
Menopause; 2006; 13(5):780-6. PubMed ID: 16894334
[TBL] [Abstract][Full Text] [Related]
14. Pulsed estrogen therapy: relieving climacteric symptoms, preventing postmenopausal bone loss.
Palacios S
Climacteric; 2002 Jun; 5 Suppl 2():32-9. PubMed ID: 12482109
[TBL] [Abstract][Full Text] [Related]
15. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study.
Chandeying V; Sangthawan M
J Med Assoc Thai; 2007 Sep; 90(9):1720-6. PubMed ID: 17957910
[TBL] [Abstract][Full Text] [Related]
16. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women.
Naunton M; Al Hadithy AF; Brouwers JR; Archer DF
Menopause; 2006; 13(3):517-27. PubMed ID: 16735950
[TBL] [Abstract][Full Text] [Related]
17. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women.
Joffe H; Hall JE; Gruber S; Sarmiento IA; Cohen LS; Yurgelun-Todd D; Martin KA
Menopause; 2006; 13(3):411-22. PubMed ID: 16735938
[TBL] [Abstract][Full Text] [Related]
18. Comparison of steady state development and reduction of menopausal symptoms after oral or transdermal delivery of 17-β-estradiol in young healthy symptomatic menopausal women.
Rohr UD; Volko CD; Schindler AE
Horm Mol Biol Clin Investig; 2014 Jun; 18(3):123-36. PubMed ID: 25390008
[TBL] [Abstract][Full Text] [Related]
19. Intranasal versus transdermal matrix oestrogen replacement in Australasian women.
Davis SR; Davison SL; Wilson S; Shepherd J; Lawton B
Maturitas; 2005 Jun; 51(2):163-71. PubMed ID: 15917157
[TBL] [Abstract][Full Text] [Related]
20. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
